Venetoclax shows potential for R/R hairy cell leukemia

Published Date: 13 Mar 2023

Five out of six patients with relapsed or recurrent lymphoma responded to venetoclax alone or in combination with rituximab.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Approves New Bladder Cancer First-Line Standard of Care.

2.

UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts

3.

Surgeons are at higher risk of cancer, study suggests

4.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

5.

Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot